These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 8661211)

  • 1. A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation.
    Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Tejwani S; Hulin MS; Stanley JC
    J Surg Res; 1996 Jun; 63(1):280-6. PubMed ID: 8661211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective and less toxic reversal of low-molecular weight heparin anticoagulation by a designer variant of protamine.
    Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Schmidt R; Tejwani S; Stanley JC
    J Vasc Surg; 1995 May; 21(5):839-49; discussion 849-50. PubMed ID: 7769743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of low-molecular-weight heparin anticoagulation by synthetic protamine analogues.
    Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Fazzalari A; Nichol BJ; Vanderkooi T; Stanley JC
    J Surg Res; 1994 Jun; 56(6):586-93. PubMed ID: 8015315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low-molecular-weight heparin anticoagulation in a canine model.
    Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Downing LJ; Stanley JC
    Lab Anim Sci; 1997 Apr; 47(2):153-60. PubMed ID: 9150494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel protamine variant reversal of heparin anticoagulation in human blood in vitro.
    Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Stoneham MD; Doyle AR; Zelenock GB; Jacobs LA; Shanley CJ; TenCate VM; Stanley JC
    J Vasc Surg; 1997 Dec; 26(6):1043-8. PubMed ID: 9423721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of differing rates of protamine reversal of heparin anticoagulation.
    Wakefield TW; Hantler CB; Wrobleski SK; Crider BA; Stanley JC
    Surgery; 1996 Feb; 119(2):123-8. PubMed ID: 8571194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal.
    DeLucia A; Wakefield TW; Andrews PC; Nichol BJ; Kadell AM; Wrobleski SK; Downing LJ; Stanley JC
    J Vasc Surg; 1993 Jul; 18(1):49-58; discussion 58-60. PubMed ID: 8326659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of complement-mediated events after protamine reversal of heparin anticoagulation.
    Wakefield TW; Kirsh MM; Till GO; Brothers TE; Hantler CB; Stanley JC
    J Surg Res; 1991 Jul; 51(1):72-6. PubMed ID: 2067362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased oxygen consumption as a toxic manifestation of protamine sulfate reversal of heparin anticoagulation.
    Wakefield TW; Ucros I; Kresowik TF; Hinshaw DB; Stanley JC
    J Vasc Surg; 1989 Jun; 9(6):772-7. PubMed ID: 2724464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep.
    Montalescot G; Zapol WM; Carvalho A; Robinson DR; Torres A; Lowenstein E
    Circulation; 1990 Nov; 82(5):1754-64. PubMed ID: 2171807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of hemodynamic and hematologic effects of heparin-protamine sulfate interaction after aortic reconstruction in a canine model.
    Wakefield TW; Lindblad B; Whitehouse WM; Hantler CB; Stanley JC
    Surgery; 1986 Jul; 100(1):45-51. PubMed ID: 3726760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors.
    Lindblad B; Borgström A; Wakefield TW; Whitehouse WM; Stanley JC
    Thromb Res; 1987 Oct; 48(1):31-40. PubMed ID: 2827339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of low-molecular-weight heparins and their binding to protamine and a protamine analog using polyion-sensitive membrane electrodes.
    Ramamurthy N; Baliga N; Wakefield TW; Andrews PC; Yang VC; Meyerhoff ME
    Anal Biochem; 1999 Jan; 266(1):116-24. PubMed ID: 9887220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components.
    Schroeder M; Hogwood J; Gray E; Mulloy B; Hackett AM; Johansen KB
    Anal Bioanal Chem; 2011 Jan; 399(2):763-71. PubMed ID: 20922518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.
    Chang LC; Liang JF; Lee HF; Lee LM; Yang VC
    AAPS PharmSci; 2001; 3(3):E18. PubMed ID: 11741269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemodynamic and haematologic alterations with protamine reversal of anticoagulation: comparison of standard heparin and a low molecular weight heparin fragment.
    Lindblad B; Borgström A; Wakefield TW; Whitehouse WM; Stanley JC
    Eur J Vasc Surg; 1987 Jun; 1(3):181-5. PubMed ID: 2846368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
    Schick BP; Maslow D; Moshinski A; San Antonio JD
    Blood; 2004 Feb; 103(4):1356-63. PubMed ID: 14576044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protamine reversal of low molecular weight heparin: clinically effective?
    van Veen JJ; Maclean RM; Hampton KK; Laidlaw S; Kitchen S; Toth P; Makris M
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):565-70. PubMed ID: 21959588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.
    Lee LM; Chang LC; Wrobleski S; Wakefield TW; Yang VC
    AAPS PharmSci; 2001; 3(3):E19. PubMed ID: 11741270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
    Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.